351 related articles for article (PubMed ID: 37895830)
1. Patient-Derived Cellular Models for Polytarget Precision Medicine in Pantothenate Kinase-Associated Neurodegeneration.
Álvarez-Córdoba M; Talaverón-Rey M; Povea-Cabello S; Cilleros-Holgado P; Gómez-Fernández D; Piñero-Pérez R; Reche-López D; Munuera-Cabeza M; Suárez-Carrillo A; Romero-González A; Romero-Domínguez JM; López-Cabrera A; Armengol JÁ; Sánchez-Alcázar JA
Pharmaceuticals (Basel); 2023 Sep; 16(10):. PubMed ID: 37895830
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in pantothenate kinase-associated neurodegeneration.
Alvarez-Cordoba M; Villanueva-Paz M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Talaverón-Rey M; Abril-Jaramillo J; Vintimilla-Tosi AB; Sánchez-Alcázar JA
Neural Regen Res; 2019 Jul; 14(7):1177-1185. PubMed ID: 30804242
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic approach with commercial supplements for pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels.
Álvarez-Córdoba M; Reche-López D; Cilleros-Holgado P; Talaverón-Rey M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Suárez-Carrillo A; Munuera-Cabeza M; Piñero-Pérez R; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2022 Aug; 17(1):311. PubMed ID: 35945593
[TBL] [Abstract][Full Text] [Related]
4. Alpha-lipoic acid supplementation corrects pathological alterations in cellular models of pantothenate kinase-associated neurodegeneration with residual PANK2 expression levels.
Talaverón-Rey M; Álvarez-Córdoba M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Gómez-Fernández D; Romero-González A; Suárez-Carrillo A; Munuera-Cabeza M; Cilleros-Holgado P; Reche-López D; Piñero-Pérez R; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2023 Apr; 18(1):80. PubMed ID: 37046296
[TBL] [Abstract][Full Text] [Related]
5. Down regulation of the expression of mitochondrial phosphopantetheinyl-proteins in pantothenate kinase-associated neurodegeneration: pathophysiological consequences and therapeutic perspectives.
Álvarez-Córdoba M; Talaverón-Rey M; Villalón-García I; Povea-Cabello S; Suárez-Rivero JM; Suárez-Carrillo A; Munuera-Cabeza M; Salas JJ; Sánchez-Alcázar JA
Orphanet J Rare Dis; 2021 May; 16(1):201. PubMed ID: 33952316
[TBL] [Abstract][Full Text] [Related]
6. Pantothenate Rescues Iron Accumulation in Pantothenate Kinase-Associated Neurodegeneration Depending on the Type of Mutation.
Álvarez-Córdoba M; Fernández Khoury A; Villanueva-Paz M; Gómez-Navarro C; Villalón-García I; Suárez-Rivero JM; Povea-Cabello S; de la Mata M; Cotán D; Talaverón-Rey M; Pérez-Pulido AJ; Salas JJ; Pérez-Villegas EM; Díaz-Quintana A; Armengol JA; Sánchez-Alcázar JA
Mol Neurobiol; 2019 May; 56(5):3638-3656. PubMed ID: 30173408
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and Treatment of Pantothenate Kinase-Associated Neurodegeneration (PKAN): A Systematic Review.
Pohane MR; Dafre R; Sontakke NG
Cureus; 2023 Sep; 15(9):e46135. PubMed ID: 37900501
[TBL] [Abstract][Full Text] [Related]
8. A Potential Citrate Shunt in Erythrocytes of PKAN Patients Caused by Mutations in Pantothenate Kinase 2.
Werning M; Dobretzberger V; Brenner M; Müllner EW; Mlynek G; Djinovic-Carugo K; Baron DM; Fragner L; Bischoff AT; Büchner B; Klopstock T; Weckwerth W; Salzer U
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204826
[TBL] [Abstract][Full Text] [Related]
9. Novel homozygous PANK2 mutation causing atypical pantothenate kinase-associated neurodegeneration (PKAN) in a Cypriot family.
Tanteles GA; Spanou-Aristidou E; Antoniou C; Christophidou-Anastasiadou V; Kleopa KA
J Neurol Sci; 2014 May; 340(1-2):233-6. PubMed ID: 24655737
[TBL] [Abstract][Full Text] [Related]
10. Pantothenate kinase-associated neurodegeneration (PKAN) and PLA2G6-associated neurodegeneration (PLAN): review of two major neurodegeneration with brain iron accumulation (NBIA) phenotypes.
Kurian MA; Hayflick SJ
Int Rev Neurobiol; 2013; 110():49-71. PubMed ID: 24209433
[TBL] [Abstract][Full Text] [Related]
11. Exploring Yeast as a Study Model of Pantothenate Kinase-Associated Neurodegeneration and for the Identification of Therapeutic Compounds.
Ceccatelli Berti C; Gilea AI; De Gregorio MA; Goffrini P
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396642
[TBL] [Abstract][Full Text] [Related]
12. Harmful Iron-Calcium Relationship in Pantothenate kinase Associated Neurodegeneration.
Santambrogio P; Ripamonti M; Paolizzi C; Panteghini C; Carecchio M; Chiapparini L; Raimondi M; Rubio A; Di Meo I; Cozzi A; Taverna S; De Palma G; Tiranti V; Levi S
Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32456086
[TBL] [Abstract][Full Text] [Related]
13. Pantethine treatment is effective in recovering the disease phenotype induced by ketogenic diet in a pantothenate kinase-associated neurodegeneration mouse model.
Brunetti D; Dusi S; Giordano C; Lamperti C; Morbin M; Fugnanesi V; Marchet S; Fagiolari G; Sibon O; Moggio M; d'Amati G; Tiranti V
Brain; 2014 Jan; 137(Pt 1):57-68. PubMed ID: 24316510
[TBL] [Abstract][Full Text] [Related]
14. Clinical and genetic features of PKAN patients in a tertiary centre in Turkey.
Akcakaya NH; Iseri SU; Bilir B; Battaloglu E; Tekturk P; Gultekin M; Akar G; Yigiter R; Hanagasi H; Alp R; Cagirici S; Eraksoy M; Ozbek U; Yapici Z
Clin Neurol Neurosurg; 2017 Mar; 154():34-42. PubMed ID: 28113101
[TBL] [Abstract][Full Text] [Related]
15. Knock-down of pantothenate kinase 2 severely affects the development of the nervous and vascular system in zebrafish, providing new insights into PKAN disease.
Zizioli D; Tiso N; Guglielmi A; Saraceno C; Busolin G; Giuliani R; Khatri D; Monti E; Borsani G; Argenton F; Finazzi D
Neurobiol Dis; 2016 Jan; 85():35-48. PubMed ID: 26476142
[TBL] [Abstract][Full Text] [Related]
16. PKAN neurodegeneration and residual PANK2 activities in patient erythrocytes.
Werning M; Müllner EW; Mlynek G; Dobretzberger V; Djinovic-Carugo K; Baron DM; Prokisch H; Büchner B; Klopstock T; Salzer U
Ann Clin Transl Neurol; 2020 Aug; 7(8):1340-1351. PubMed ID: 32705819
[TBL] [Abstract][Full Text] [Related]
17. Acanthocytosis and the c.680 A>G Mutation in the PANK2 Gene: A Study Enrolling a Cohort of PKAN Patients from the Dominican Republic.
Schiessl-Weyer J; Roa P; Laccone F; Kluge B; Tichy A; De Almeida Ribeiro E; Prohaska R; Stoeter P; Siegl C; Salzer U
PLoS One; 2015; 10(4):e0125861. PubMed ID: 25915509
[TBL] [Abstract][Full Text] [Related]
18. Unraveling the Hallervorden-Spatz syndrome: pantothenate kinase-associated neurodegeneration is the name.
Hayflick SJ
Curr Opin Pediatr; 2003 Dec; 15(6):572-7. PubMed ID: 14631201
[TBL] [Abstract][Full Text] [Related]
19. Rational Design of Novel Therapies for Pantothenate Kinase-Associated Neurodegeneration.
Thakur N; Klopstock T; Jackowski S; Kuscer E; Tricta F; Videnovic A; Jinnah HA
Mov Disord; 2021 Sep; 36(9):2005-2016. PubMed ID: 34002881
[TBL] [Abstract][Full Text] [Related]
20. Siblings with the adult-onset slowly progressive type of pantothenate kinase-associated neurodegeneration and a novel mutation, Ile346Ser, in PANK2: clinical features and (99m)Tc-ECD brain perfusion SPECT findings.
Doi H; Koyano S; Miyatake S; Matsumoto N; Kameda T; Tomita A; Miyaji Y; Suzuki Y; Sawaishi Y; Kuroiwa Y
J Neurol Sci; 2010 Mar; 290(1-2):172-6. PubMed ID: 20006850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
